Navigation Links
VaxGen and Raven Terminate Merger Agreement
Date:3/28/2008

SOUTH SAN FRANCISCO, Calif., March 28 /PRNewswire-FirstCall/ -- VaxGen, Inc. (OTC Bulletin Board: VXGN), a biopharmaceutical company, announced that the Company and Raven biotechnologies, inc. have mutually agreed to terminate their merger agreement in light of stronger than anticipated opposition to the proposed merger by VaxGen stockholders. In addition, VaxGen's Board has withdrawn from stockholder consideration the proposed 2008 Equity Incentive Plan, which is unnecessary in the absence of the merger. It has recently become apparent to both companies that despite initial indications to the contrary, the proposed merger and related equity plan proposals would be rejected by VaxGen stockholders.

(Logo: http://www.newscom.com/cgi-bin/prnh/19991112/VAXGENLOGO )

"We are obviously very disappointed that the proposed merger with Raven was not approved by our stockholders," said James P. Panek, VaxGen President and CEO. "Despite the strong support of some institutions, and solid support by so many individual investors, it has become quite clear that there is sufficient opposition, such that this merger will not be approved."

VaxGen intends to open the Special Meeting of Stockholders scheduled for Friday, March 28th, but will adjourn the meeting without taking any action. The Board of Directors intends to immediately assess the Company's strategic alternatives, including a possible liquidation of the Company.

About VaxGen

VaxGen is a biopharmaceutical company based in South San Francisco, California. The company owns a state-of-the-art biopharmaceutical manufacturing facility with a 1,000-liter bioreactor that can be used to make cell culture or microbial biologic products. For more information, please visit the company's web site at http://www.vaxgen.com.

Note: This press release contains "forward-looking statements" within the meaning of the federal securities laws, including statements regarding the holding of the Special Meeting of Stockholders and the Board of Directors' plans to assess strategic alternatives. These statements are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated. Additional information concerning these and other risk factors is contained in VaxGen's Annual Report on Form 10-K for the year ended December 31, 2007. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date of this release. VaxGen undertakes no obligation to update publicly any forward- looking statements to reflect new information, events, or circumstances after the date of this release except as required by law.


'/>"/>
SOURCE VaxGen, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. VaxGen Issues Rebuttal to MedCap Letter
2. VaxGen Common Stock Now Quoted on OTC Bulletin Board
3. VaxGen Reports Financial Update
4. VaxGen to Present at the 10th Annual BIO CEO and Investor Conference
5. VaxGen and Raven Announce Form S4 Registration Statement Declared Effective
6. VaxGen Stockholders Overwhelmingly Approve Reverse Split Proposal
7. VaxGen Common Stock Expected to Qualify for Quotation on OTC Bulletin Board
8. VaxGen Addresses MPM Claims in Letter to Stockholders
9. VaxGen Files Last Outstanding Periodic Report With SEC
10. Jack Anthony to Resign From VaxGens Board After Accepting CEO Position at Osprey Pharmaceuticals
11. VaxGen Files First Quarter 2007 Financials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... (PRWEB) , ... April 25, 2017 , ... LABS, Inc. ... were added to its extensive test menu: Nucleic Acid Testing (NAT) for ZIKV; ... LABS was only able to offer NAT screening for blood donors under an Investigational ...
(Date:4/25/2017)... Ca (PRWEB) , ... April 25, 2017 , ... As ... in the series will explore the laboratory testing for DIC in order to illuminate ... hypercoagulable disorder which can occur in hospitalized patients resulting in a high degree of ...
(Date:4/25/2017)... Los Gatos, California (PRWEB) , ... April 25, ... ... of business, Analytical Services and Metrology Partners.     , Covalent’s Analytical Services ... labs. Most samples can be measured within 24 hours of receipt. There are ...
(Date:4/21/2017)... ... April 21, 2017 , ... Having worked on the design of ... pleased to introduce it to top lab design architects from around the country at ... VP of Industrial Design and Engineering Greg Casey will be at the show, where ...
Breaking Biology Technology:
(Date:3/30/2017)... The research team of The Hong Kong ... identification by adopting ground breaking 3D fingerprint minutiae recovery and matching ... and accuracy for use in identification, crime investigation, immigration control, security ... ... A research team led by ...
(Date:3/28/2017)... PUNE, India , March 28, 2017 ... (Analog, IP, Biometrics), Hardware (Camera, Monitors, Servers, Storage Devices), ... Maintenance), Vertical, and Region - Global Forecast to 2022", ... 30.37 Billion in 2016 and is projected to reach ... 15.4% between 2017 and 2022. The base year considered ...
(Date:3/24/2017)... 24, 2017 Research and Markets has announced ... Analysis & Trends - Industry Forecast to 2025" report to ... The ... a CAGR of around 15.1% over the next decade to reach ... analyzes the market estimates and forecasts for all the given segments ...
Breaking Biology News(10 mins):